Type 2 diabetes mellitus (T2D) is characterized by persistent hyperglycemia, affects more than 370 million people worldwide, and is a major cause of morbidity and mortality (Kahn et al., 2014) . For many decades, therapeutic strategies aimed at glucose lowering have predominantly focused on drugs that stimulate the release of insulin from the pancreas or improve insulin-stimulated glucose uptake in peripheral tissues (Figure 1 ). However, there is considerable heterogeneity in therapeutic response, and many people require multiple medications to lower blood glucose to a level that reduces the risks of long-term cardiovascular, renal, and eye complications. As such, there is a need to identify additional mechanisms that can be effectively and safely targeted to treat people with T2D. Human genetic studies are a powerful tool to enable the discovery of new molecules/pathways that contribute to natural variation in specific traits (e.g., blood glucose levels) or mediate the risk of disease (T2D). A recent study by Nelson and colleagues found that the percentage of drug mechanisms with direct support from human genetic studies increased significantly across the drug development pipeline, suggesting that selecting genetically supported drug targets could improve the success rate of drug development (Nelson et al., 2015) . However, going from genetic association to disease mechanism can be challenging, particularly when exploring genome-wide association studies (GWAS), where risk-associated variants often lie in noncoding regions or in regions containing multiple genes.
In this issue of Cell, Rusu and colleagues take on this challenge (Rusu et al., 2017) . The authors set out to explore a cluster of genetic variants on chromosome 17p13 associated with T2D in a GWAS of Mexican adults, a population with a very high prevalence of T2D (SIGMA Type 2 Diabetes Consortium et al., 2014). They first refined the risk haplotype at 17p13, which has a high allele frequency among Mexicans, identifying a set of 18 variants in strong linkage disequilibrium with the top risk variant; these variants are associated with an approximately 30% increase in T2D risk in this population. They showed that 12 noncoding variants span the SLC16A11 gene locus and that there are four missense variants in the SLC16A11 gene itself.
SLC16A11 is a member of the 14-strong SLC16 gene family, which encodes monocarboxylate transporters (MCTs). MCTs transport simple monocarboxylic acids, such as lactate, pyruvate, and ketone bodies, across biological membranes playing an important role in cellular metabolism, notably as facilitators of the Cori cycle by shuttling lactate out of muscle cells and into liver cells, as well as moving pyruvate and ketone bodies between producing and utilizing cells within the same organ (Halestrap, 2013) . In a series of molecular studies, they characterized the function of MCT11 (the transporter encoded by the SLC16A11 gene), confirming its location at the cell surface as well as in internal membranes. Heterologous expression of SLC16A11 in a human cell line and use of pyruvate as a test substrate established MCT11 as a proton-coupled transporter capable of efficiently shuttling monocarboxylates in and out of the cell.
They went on to demonstrate that the risk haplotype diminishes MCT11 function in at least two ways. First, they show that SLC16A11 gene expression is reduced in liver tissue taken from carriers of the risk haplotype in a gene dose-dependent manner. Second, they show that the four coding variants associated with T2D risk reduce cell-membrane expression of the transporter, which can be attributed to diminished interaction with a chaperone protein, Basigin; this results in significantly reduced transporter activity. Finally, to analyze the consequences of reduced MCT11 function, the authors knock down SLC16A11 in primary human hepatocytes and find that levels of intracellular acylcarnitines, diacylglycerols (DAGs), and triacylglycerols (TAGs) and extracellular TAGs are significantly increased in human hepatocytes treated with small interfering RNAs (siRNAs) targeting SLC16A11. Together, these changes suggest that MCT11 affects cellular fatty acid and lipid metabolism (Figure 1) , although the precise mechanisms by which these effects occur remain to be explored. Cumulatively, these studies provide evidence for loss of function of SLC16A11 as a plausible mechanism linking common variants at 17p13 and the risk of T2D in variant carriers.
A number of important follow-up questions emerge from this study. The authors reasonably postulate that SLC16A11 variants play a role in T2D risk by affecting hepatic lipid metabolism, although a more detailed understanding of how MCT11 functions to affect nutrient flux is needed; in particular, is this a transporter with narrow substrate specificities? Additionally, MCT11 may have a functional role in other tissues, in particular the pancreas where MCT1 (encoded by SLC16A1 and functionally related to SLC16A11) has previously been shown to modulate pyruvate uptake and pyruvatestimulated insulin release by b cells (Otonkoski et al., 2007) . Detailed metabolic studies of homozygous and heterozygous carriers of the risk haplotype versus nonvariant carriers should be particularly informative. Finally, the authors suggest that enhancing the transporter's activity may have therapeutic benefits. Such an approach is certainly plausible; in fact, targeting this group of molecules is an area of considerable interest as rare penetrant mutations in several solute transporters have been identified in a number of monogenic diseases (Lin et al., 2015) . Therapies targeting MCT11 may be particularly effective in people whose T2D is driven by this mechanism/ pathway as seen in monogenic forms of diabetes where patients are particularly responsive to certain classes of anti-diabetic drugs (Gloyn et al., 2004; Pearson et al., 2003) . Further physiological studies will be needed to test whether modest differences in MCT11 activity contribute to metabolic phenotypes in non-variant Rusu et al. found that a set of variants in the gene-encoding monocarboxylate transporter 11 (MCT11) impaired cell-surface localization of the protein by reducing its interaction with a chaperone protein, Basigin. Their work suggests that drugs that rescue MCT11 activity could be useful in the treatment of T2D.
carriers and thus whether any potential therapeutic strategy aimed at MCT11 may have broader clinical relevance.
It is intriguing that this risk haplotype is highly prevalent in Mexicans but not in those of European ancestry, in whom most GWAS have been conducted to date. The reasons for this high prevalence would be interesting to explore. For example, does this haplotype confer a selective advantage, and if so, does it do so by favoring energy storage, thereby acting as a useful defense against starvation? In summary, Rusu et al. provide an elegant example of how large-scale genetic studies can facilitate the discovery of new therapeutic targets in common complex diseases such as T2D. While cumulatively, T2D GWAS have been successful in identifying a large number of loci that contribute to the risk of disease (Fuchsberger et al., 2016) , a significant amount of the estimated heritability cannot be accounted for, suggesting that much remains to be discovered. The authors have taken an important first step by highlighting the role of MCT11 in nutrient flux. Their work raises a series of questions that need to be addressed in model organisms, and critically in humans, if the promise of targeting MCT11 as a potential therapy for T2D is to be fulfilled.
A long-standing question in cell biology is how endocytic vesicles and tubules detach from the plasma membrane in the absence of constriction by dynamin. In this issue of Cell, Simunovic et al. describe an elegant biophysical model in which friction between lipids and BAR-domain proteins drives the scission of elongating membrane tubules.
Eukaryotic cells are, by definition, organized into membrane-delimited compartments whose shape is governed by membrane-sculpting proteins and connected to one another by a constant flux of vesicular fission and fusion. These fission and fusion events are pivotal to the very existence of eukaryotic cells. Yet their mechanisms, involving lipid rearrangements too dynamic for structural biology and too small for cell imaging, have been remarkably difficult to uncover. Research in membrane fission and fusion is thus characterized by many uncertainties and spirited debates; but this is not the sort of ''friction'' referred to in the title. In this issue of Cell, Simunovic et al. (2017) provide compelling experimental and theoretical support for the idea that mechanical friction between Bin/Amphiphysin/Rvs (BAR) domain proteins and membrane lipids leads to membrane scission.
BAR domains form banana-shaped dimers whose crescent shapes (Peter et al., 2004) bind membranes, where they assemble into coats for tubular vesicles (Frost et al., 2008) that are abundant in endosomal pathways. Shorter regions of cylindrical geometry occur at the necks connecting nascent spherical vesicles to their parent membranes. The best known of these are clathrin-coated vesicles (CCVs). In mammalian cells, the GTPase dynamin
